■为了检查神经降压素的血清浓度,慢性失眠障碍(CID)患者的pannexin-1和sestrin-2及其与主观和客观睡眠质量和认知功能的相关性。
■连续纳入65例D患者,同期56例睡眠良好者作为健康对照(HC)。神经降压素的血清水平,通过酶联免疫吸附测定法测量pannexin-1和setrin-2。使用匹兹堡睡眠质量指数(PSQI)和多导睡眠图评估睡眠质量,用17项汉密尔顿抑郁量表评价情绪。一般认知功能用中文-北京版蒙特利尔认知评估量表进行评估,空间记忆用蓝色天鹅绒竞技场测试(BVAT)进行评估。
■相对于HC,CID患者的神经降压素(t=5.210,p<0.001)和pannexin-1(Z=-4.169,p<0.001)水平较高,和较低水平的sestrin-2(Z=-2.438,p=0.015)。在客观的睡眠测量方面,pannexin-1与总睡眠时间(r=0.562,p=0.002)和睡眠效率(r=0.588,p=0.001)呈正相关,与睡眠开始后的觉醒时间(r=-0.590,p=0.001)和觉醒时间(r=-0.590,p=0.001)呈负相关;sestrin-2与快速眼动睡眠百分比(r=0.442,p=0.016)呈正相关,与非快速眼动睡眠阶段2呈负相关(r=-0.394,p=0.034)。根据性别调整,年龄和HAMD,pannexin-1仍然与上述客观睡眠指标有关,但sestrin-2仅与唤醒时间呈负相关(r=-0.446,p=0.022)。然而,这些生物标志物与主观睡眠质量(PSQI评分)无显著相关性.神经降压素和pannexin-1的血清浓度与BVAT中的平均错误距离呈正相关。根据性别调整,年龄和抑郁,神经降压素与MoCA评分呈负相关(r=-0.257,p=0.044),pannexin-1与BVAT中的平均错误距离呈正相关(r=0.270,p=0.033)。
■TheCID患者的血清中神经降压素和pannexin-1增加,setstrin-2减少,表明神经元功能障碍,这可能与客观测量的睡眠质量差和认知功能障碍有关。
UNASSIGNED: To examine serum concentrations of neurotensin, pannexin-1 and sestrin-2, and their correlations with subjective and objective sleep quality and cognitive function in the patients with chronic insomnia disorder (CID).
UNASSIGNED: Sixty-five CID patients were enrolled continuously and fifty-six good sleepers in the same period were served as healthy controls (HCs). Serum levels of neurotensin, pannexin-1 and sestrin-2 were measured by enzyme-linked immunosorbent assays. Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) and polysomnography, and mood was evaluated by 17-item Hamilton Depression Rating Scale. General cognitive function was assessed with the Chinese-Beijing Version of Montreal Cognitive Assessment and spatial memory was evaluated by Blue Velvet Arena Test (BVAT).
UNASSIGNED: Relative to the HCs, the CID sufferers had higher levels of neurotensin (t=5.210, p<0.001) and pannexin-1 (Z=-4.169, p<0.001), and lower level of sestrin-2 (Z=-2.438, p=0.015). In terms of objective sleep measures, pannexin-1 was positively associated with total sleep time (r=0.562, p=0.002) and sleep efficiency (r=0.588, p=0.001), and negatively with wake time after sleep onset (r=-0.590, p=0.001) and wake time (r=-0.590, p=0.001); sestrin-2 was positively associated with percentage of rapid eye movement sleep (r=0.442, p=0.016) and negatively with non-rapid eye movement sleep stage 2 in the percentage (r=-0.394, p=0.034). Adjusted for sex, age and HAMD, pannexin-1 was still associated with the above objective sleep measures, but sestrin-2 was only negatively with wake time (r=-0.446, p=0.022). However, these biomarkers showed no significant correlations with subjective sleep quality (PSQI score). Serum concentrations of neurotensin and pannexin-1 were positively associated with the mean erroneous distance in the BVAT. Adjusted for sex, age and depression, neurotensin was negatively associated with MoCA score (r=-0.257, p=0.044), pannexin-1 was positively associated with the mean erroneous distance in the BVAT (r=0.270, p=0.033).
UNASSIGNED: The CID patients had increased neurotensin and pannexin-1 and decreased sestrin-2 in the serum levels, indicating neuron dysfunction, which could be related to poor sleep quality and cognitive dysfunction measured objectively.